Nanobiotix Newswire

Nanobiotix Newswire

Comprehensive Real-Time News Feed for Nanobiotix.

Results 1 - 20 of 90 in Nanobiotix

  1. Nanometrics Inc. (NANO) Releases Q3 Earnings GuidanceRead the original story w/Photo

    3 hrs ago | Daily Political

    Nanometrics Inc. updated its third quarter earnings guidance on Tuesday. The company provided EPS guidance of $0.23-0.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.32.

    Comment?

  2. Nanometrics Inc. (NANO) Posts Earnings Results, Misses Estimates By $0.01 EPSRead the original story w/Photo

    4 hrs ago | AmericanBankingNews.com

    Nanometrics Inc. issued its earnings results on Tuesday. The company reported $0.26 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.27 by $0.01.

    Comment?

  3. Nanometrics Inc. (NANO) Sees Large Volume IncreaseRead the original story w/Photo

    Monday | Daily Political

    Nanometrics Inc. shares saw an uptick in trading volume on Monday . 220,809 shares traded hands during trading, an increase of 28% from the previous session's volume of 172,197 shares.The stock last traded at $22.24 and had previously closed at $21.88.

    Comment?

  4. Voce Capital Management LLC Buys New Stake in Nanometrics Inc.Read the original story w/Photo

    Monday | Daily Political

    Voce Capital Management LLC acquired a new position in shares of Nanometrics Inc. during the first quarter, Holdings Channel reports. The institutional investor acquired 173,586 shares of the company's stock, valued at approximately $2,750,000.

    Comment?

  5. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Friday Jul 22 | Business Wire

    The report brings together facts and figures ab... )--A.M. Best has affirmed the financial strength rating of A++ and the issuer credit ratings of "aa+" of the property/casualty subsidiaries of Th... )--Research and Markets has announced the addition of the "Market Insight - Building Information Modeling in the Global Construction Market" report to their offering. Th... )--FUND db x-trackers Stoxx Europe 600 Industrial Goods UCITS ETF DEALING DATE 21-Jul-16 NAV PER SHARE EUR74.2940 NUMBER OF SHARES IN ISSUE 473,843 CODE )--BIO and Pennsylvania Bio commend Governor Tom Wolf for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines.

    Comment?

  6. Nanoco Announces 7-Year Supply and Licensing Agreement with Leading...Read the original story w/Photo

    Friday Jul 22 | Freshnews

    Nanoco Announces 7-Year Supply and Licensing Agreement with Leading Display Optical Films Manufacturer Wah Hong Industrial to Market Cadmium-free Quantum Dots Nanoco Group plc , a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, today announced it has signed a seven-year supply and licensing agreement with Wah Hong Industrial Corporation , a leading Taiwanese manufacturer and supplier of optical films. Under the terms of the agreement, Nanoco will supply its cadmium-free quantum dot resin, manufactured at the company's plant in Runcorn, UK.

    Comment?

  7. Nanometrics Inc. (NANO) Trading Down 1.5%Read the original story w/Photo

    Tuesday Jul 19 | Daily Political

    Nanometrics Inc. shares fell 1.5% on Monday . The company traded as low as $21.64 and last traded at $21.67, with a volume of 131,354 shares changing hands.

    Comment?

  8. Nanobiotix Revenue For Q2 2016Read the original story

    Thursday Jul 14 | BioSpace

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the second quarter of 2016. NANOBIOTIX's revenue during the second quarter of 2016 corresponds to the upfront payment from Taiwan-based PharmaEngine.

    Comment?

  9. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Wednesday Jul 13 | Business Wire

    ... par la sociA tA Carrefour (Paris:CA) A la sociA tA Oddo C... )--Regulatory News: NANOBIOTIX (Euronext : NANO - ISIN: FR0011341205) (Paris:NANO), sociA tA franA aise pionniA re en nanomA decine dA veloppant ...

    Comment?

  10. Nanobiotix Reports Successful Results From Phase I/II Trial Of NBTXR3 In Head & Neck CancerRead the original story

    Wednesday Jul 6 | BioSpace

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx in frail and elderly patients. Nanobiotix's lead product, NBTXR3, is a first-in-class nanoparticle radio-enhancer designed for direct injection into cancerous tumors and engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to surrounding healthy tissues.

    Comment?

  11. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Wednesday Jul 6 | Business Wire

    Nanobiotix annonce des rsultats positifs dans l'essai de Phase I/II sur les cancers de la tte et du cou avec le produit NBTXR3 )--Regulatory News : NANOBIOTIX , sociA tA franA aise pionniA re en nanomA decine dA veloppant NanoXray, une a... )--Fitch Ratings has affirmed the Long-Term Foreign and Local Currency Issuer Default Ratings of Banco Pine S.A. at 'BB-'/Outlook Negative.

    Comment?

  12. Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck CancerRead the original story w/Photo

    Wednesday Jul 6 | Business Wire

    Figure: Patient treated with NBTXR3; 3D scan reconstruction before and after radiotherapy, showing tumor reduction and presence of the nanoparticles in the tumor with no leakage in surrounding healthy tissues. . NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx in frail and elderly patients.

    Comment?

  13. Radiotherapy enhancer brings back mass medicineRead the original story

    Jun 21, 2016 | Nanotechweb.org

    Radiotherapy is used in 60% of cancer cases, but it is prone to damaging nearby healthy cells and ineffective against cancer that has spread in metastasis. Nanobiotix has developed a nanomaterial product that enhances the x ray exposure to tumour cells without increasing the dose inflicted on nearby healthy cells.

    Comment?

  14. Nanobiotix Announces Exercise of Warrants by Capital Venture InternationalRead the original story w/Photo

    Jun 14, 2016 | Business Wire

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces that it has received a notification from Capital Ventures International to exercise warrants over 50,000 ordinary shares of the Company, at an exercise price of EUR 17.87 per share representing a share capital increase of an amount, in aggregate, equal to EUR 893,500. Admission of the new ordinary shares is expected to occur on June 14, 2016 to trading on the regulated market of Euronext in Paris.

    Comment?

  15. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Jun 2, 2016 | Business Wire

    ... A 01-Jun-16 NAV PER SHARE A USD9.4176 NUMBER OF SHARES IN ISSUE A 28,800,000 CODE A 20.5334 )--Regulatory News: Nanobiotix (Paris:NANO) : NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en ...

    Comment?

  16. Nanobiotix Receives U.S. $1 Million Milestone Payment From PharmaEngine, Inc.Read the original story

    May 31, 2016 | BioSpace

    First patient injected with NBTXR3 in soft tissue sarcoma registration phase in Asia Paris, France, Cambridge, MA, USA May 31, 2016 - NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, receives a US$1m milestone payment from its Taiwan-based partner PharmaEngine. The US$1m payment from PharmaEngine has been triggered by the injection of the first patient undergoing treatment in Nanobiotix' Soft Tissue Sarcoma pivotal phase at a hospital in the Philippines.

    Comment?

  17. PharmaEngine Announces Initiation of Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue...Read the original story

    May 31, 2016 | Freshnews

    PharmaEngine Inc. announced today that the first patient has been dosed in a global pivotal phase II/III trial of PEP503 in soft tissue sarcoma at Perpetual Succour Hospital, Cebu, Philippines. This multi-national, randomized, open-label, two-arm pivotal phase II/III trial, referred to as Study 301 , is being conducted in partnership with PharmaEngine's partner, Nanobiotix S.A. .

    Comment?

  18. PharmaEngine Announces Initiation of Global Pivotal Trial of PEP503...Read the original story w/Photo

    May 31, 2016 | PR Newswire

    ... referred to as Study 301 (Act.in.sarc study), is being conducted in partnership with PharmaEngine's partner, Nanobiotix S.A. (Euronext: NANO). PharmaEngine is the co-sponsor of this Study 301 in the Asia-Pacific Region. The primary objective of ...

    Comment?

  19. Nanobiotix Establishes Promising Preclinical Proof-Of-Concept In Immuno OncologyRead the original story

    May 30, 2016 | BioSpace

    Paris, France, Cambridge, MA, USA May 31, 2016 - NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept with the lead product NBTXR3 for its new program in Immuno Oncology .

    Comment?

  20. Novel Drug Delivery Systems in Cancer Therapy Market Future Growth Analysis 2014 - 2020Read the original story w/Photo

    May 30, 2016 | SBWire

    ... Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation. About MRRSE MRRSE stands for Market Research Reports ...

    Comment?